<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Exp Med</journal-id><journal-id journal-id-type="hwp">jem</journal-id><journal-title-group><journal-title>The Journal of Experimental Medicine</journal-title></journal-title-group><issn pub-type="ppub">0022-1007</issn><issn pub-type="epub">1540-9538</issn><publisher><publisher-name>The Rockefeller University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19635861</article-id><article-id pub-id-type="publisher-id">20082152</article-id><article-id pub-id-type="doi">10.1084/jem.20082152</article-id><article-categories><subj-group subj-group-type="heading"><subject>Brief Definitive Report</subject></subj-group></article-categories><title-group><article-title>Hepatocyte-specific NEMO deletion promotes NK/NKT cell&#x02013; and TRAIL-dependent liver damage</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Beraza</surname><given-names>Naiara</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Malato</surname><given-names>Yann</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sander</surname><given-names>Leif E.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Al-Masaoudi</surname><given-names>Malika</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Freimuth</surname><given-names>Julia</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Riethmacher</surname><given-names>Dieter</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Gores</surname><given-names>Gregory J.</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Roskams</surname><given-names>Tania</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Liedtke</surname><given-names>Christian</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Trautwein</surname><given-names>Christian</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label><institution>Department of Internal Medicine III, University Hospital (RWTH) Aachen, Aachen 5205, Germany</institution></aff><aff id="aff2"><label>2</label><institution>Human Genetics Division, Southampton University School of Medicine, Southampton General Hospital, Southampton SO16, England, UK</institution></aff><aff id="aff3"><label>3</label><institution>Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic College of Medicine, Rochester, MN 55905</institution></aff><aff id="aff4"><label>4</label><institution>Department of Pathology, Catholic University of Leuven, Leuven B-3000, Belgium</institution></aff><author-notes><corresp>CORRESPONDENCE Christian Trautwein: <email>ctrautwein@ukaachen.de</email></corresp><fn><p>N. Beraza's present address is CICbioGUNE, Technology Park of Bizkaia, Derio 48160, Spain.</p></fn></author-notes><pub-date pub-type="ppub"><day>3</day><month>8</month><year>2009</year></pub-date><volume>206</volume><issue>8</issue><fpage>1727</fpage><lpage>1737</lpage><history><date date-type="received"><day>25</day><month>9</month><year>2008</year></date><date date-type="accepted"><day>30</day><month>6</month><year>2009</year></date></history><permissions><copyright-statement>&#x000a9; 2009 Beraza et al.</copyright-statement><copyright-year>2009</copyright-year><license license-type="openaccess" xlink:href="http://creativecommons.org/licenses/by/2.0/"><license-p>This article is distributed under the terms of an Attribution&#x02013;Noncommercial&#x02013;Share Alike&#x02013;No Mirror Sites license for the first six months after the publication date (see <ext-link ext-link-type="uri" xlink:href="http://www.jem.org/misc/terms.shtml">http://www.jem.org/misc/terms.shtml</ext-link>). After six months it is available under a Creative Commons License (Attribution&#x02013;Noncommercial&#x02013;Share Alike 3.0 Unported license, as described at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0/">http://creativecommons.org/licenses/by-nc-sa/3.0/</ext-link>).</license-p></license></permissions><abstract><p>Nuclear factor &#x003ba;B (NF-&#x003ba;B) is one of the main transcription factors involved in regulating apoptosis, inflammation, chronic liver disease, and cancer progression. The IKK complex mediates NF-&#x003ba;B activation and deletion of its regulatory subunit NEMO in hepatocytes (NEMO<sup>&#x00394;hepa</sup>) triggers chronic inflammation and spontaneous hepatocellular carcinoma development. We show that NEMO<sup>&#x00394;hepa</sup> mice were resistant to Fas-mediated apoptosis but hypersensitive to tumor necrosis factor&#x02013;related apoptosis-inducing ligand (TRAIL) as the result of a strong up-regulation of its receptor DR5 on hepatocytes. Additionally, natural killer (NK) cells, the main source of TRAIL, were activated in NEMO<sup>&#x00394;hepa</sup> livers. Interestingly, depletion of the NK1.1<sup>+</sup> cells promoted a significant reduction of liver inflammation and an improvement of liver histology in NEMO<sup>&#x00394;hepa</sup> mice. Furthermore, hepatocyte-specific NEMO deletion strongly sensitized the liver to concanavalin A (ConA)&#x02013;mediated injury. The critical role of the NK cell/TRAIL axis in NEMO<sup>&#x00394;hepa</sup> livers during ConA hepatitis was further confirmed by selective NK cell depletion and adoptive transfer of TRAIL-deficient<sup>&#x02212;/&#x02212;</sup> mononuclear cells. Our results uncover an essential mechanism of NEMO-mediated protection of the liver by preventing NK cell tissue damage via TRAIL/DR5 signaling. As this mechanism is important in human liver diseases, NEMO<sup>&#x00394;hepa</sup> mice are an interesting tool to give insight into liver pathophysiology and to develop future therapeutic strategies.</p></abstract></article-meta></front><body><p>The transcription factor NF-&#x003ba;B is essential for liver homeostasis, as it is involved in controlling the balance between survival and death signals (<xref ref-type="bibr" rid="bib14">Luo et al., 2005</xref>). Upon ligand binding, distinct receptors stimulate the IKK complex (IKK1/IKK&#x003b1;, IKK2/IKK&#x003b2;, and IKK&#x003b3;/NEMO), which initiates NF-&#x003ba;B activation. The regulatory subunit IKK&#x003b3;/NEMO is crucial during this process, as NEMO deletion results in complete NF-&#x003ba;B inhibition and embryonic lethality.</p><p>Hepatocyte-specific deletion of NEMO and its consequent NF-&#x003ba;B inhibition has detrimental effects on liver homeostasis, as it promotes spontaneous steatohepatitis, fibrosis progression, and development of hepatocellular carcinoma (HCC; <xref ref-type="bibr" rid="bib13">Luedde et al., 2007</xref>). Additionally, NEMO deletion in hepatocytes promotes severe TNF-mediated liver damage (<xref ref-type="bibr" rid="bib2">Beraza et al., 2007</xref>). However, the impact of other TNF-related cytokines on acute liver injury and their contribution to the development of the strong parenchymal damage observed in hepatocyte-specific NEMO-deleted (NEMO<sup>&#x00394;hepa</sup>) mice remains unknown.</p><p>FasL and TNF-related apoptosis-inducing ligand (TRAIL) belong to the TNF family of cytokines, as they signal through death receptors which contain cytoplasmic death domains (<xref ref-type="bibr" rid="bib21">Schutze et al., 2008</xref>). Activation of the FasL/Fas system leads to massive apoptotic cell death and fulminant hepatitis (<xref ref-type="bibr" rid="bib19">Ogasawara et al., 1993</xref>). More recently, liver steatosis has been shown to hypersensitize hepatocytes to Fas-mediated apoptosis, contributing to the progression of steatohepatitis and end-stage liver disease (<xref ref-type="bibr" rid="bib30">Zou et al., 2007</xref>).</p><p>TRAIL, via its receptor DR5, selectively induces apoptosis of transformed and virally infected hepatocytes, and NF-&#x003ba;B&#x02013;dependent signaling counteracts its detrimental effects (<xref ref-type="bibr" rid="bib15">Luo et al., 2004</xref>). The cellular responses to TRAIL have been related to the inflammatory status of the liver, and DR5 up-regulation can be mediated by free fatty acids and bile acids, indicating a link between fat metabolism and TRAIL signaling (<xref ref-type="bibr" rid="bib7">Higuchi et al., 2004</xref>; <xref ref-type="bibr" rid="bib16">Malhi et al., 2007</xref>). This is supported by findings showing high levels of liver DR5 expression in nonalcoholic steatohepatitis patients (<xref ref-type="bibr" rid="bib16">Malhi et al., 2007</xref>). Additionally, fatty liver disease activates the innate immune system by triggering NKT cells, promoting an unbalanced Th1/Th2 response in the liver (<xref ref-type="bibr" rid="bib3">Guebre-Xabier et al., 2000</xref>). This contributes to create a proinflammatory environment where high IFN-&#x003b3; expression is found. Furthermore, IFN-&#x003b3; produced by activated NKT cells strongly induces NK cells to express TRAIL (<xref ref-type="bibr" rid="bib22">Smyth et al., 2001</xref>).</p><p>Together, these data suggest that FasL and TRAIL could be involved in mediating the severe liver phenotype observed in NEMO<sup>&#x00394;hepa</sup> mice. In the present study, we aimed to characterize the implication of these cytokines and to uncover the pathophysiological mechanisms contributing to liver inflammation and further disease progression in NEMO<sup>&#x00394;hepa</sup> animals.</p><p>We demonstrate that NEMO<sup>&#x00394;hepa</sup> mice are resistant to Fas-mediated apoptosis, whereas they are hypersensitive to TRAIL-mediated cell death. Moreover, we highlight an essential role for NK cells, the main producers of TRAIL, in the spontaneous phenotype observed in NEMO<sup>&#x00394;hepa</sup> mice, as interfering with this cascade significantly improved liver homeostasis and attenuated the impact of T cell&#x02013;mediated hepatitis in NEMO<sup>&#x00394;hepa</sup> mice.</p><sec><title>RESULTS AND DISCUSSION</title><p>To better characterize the role of NEMO in hepatocytes, we generated NEMO loxP mice and crossed them with alfp-Cre transgenic animals to create NEMO<sup>f/f</sup> (WT) and NEMO<sup>&#x00394;hepa</sup> (KO) mice (<ext-link ext-link-type="uri" xlink:href="http://www.jem.org/cgi/content/full/jem.20082152/DC1">Fig. S1, A and B</ext-link>). Hepatocyte-specific NEMO deletion led to a complete lack of NF-&#x003ba;B activation after TNF stimulation, confirming our previous results (Fig. S1 C; <xref ref-type="bibr" rid="bib13">Luedde et al., 2007</xref>). Additionally, in consonance with our previous data (<xref ref-type="bibr" rid="bib13">Luedde et al., 2007</xref>), NEMO<sup>&#x00394;hepa</sup> animals exhibited spontaneously elevated TNF and TNFR1 levels, although no significant differences were found in TNFR2 expression (Fig. S1 D). Immunohistochemistry (IHC) confirmed higher TNF expression in the nonparenchymal cell compartment in NEMO<sup>&#x00394;hepa</sup> mice (Fig. S1 D). Moreover, 12-wk-old NEMO<sup>&#x00394;hepa</sup> mice displayed high ALT levels (Fig. S1 E), accompanied by signs of nonalcoholic steatohepatitis, activation of progenitor cells, profuse inflammation, and features of chronic liver damage such as hepatocyte dysplasia and anisokaryosis (Fig. S1 F, top). The combination of these events contributed to HCC development in 1-yr-old NEMO<sup>&#x00394;hepa</sup> mice, as indicated by liver tumors and higher liver weight/body weight ratio (Fig. S1, F [bottom] and G).</p><p>Hepatocyte-specific NEMO deletion promotes hypersensitivity to exogenously administered TNF; however, the animals survived this challenge (<xref ref-type="bibr" rid="bib2">Beraza et al., 2007</xref>). As NEMO deletion may also contribute to amplifying liver damage triggered by other TNF-related cytokines, we sought to investigate their implication in mediating the liver phenotype of NEMO<sup>&#x00394;hepa</sup> mice.</p><p>Fas activation promotes acute hepatic failure (<xref ref-type="bibr" rid="bib19">Ogasawara et al., 1993</xref>). Hence, stimulation with an anti-Fas mAb (Jo2, 0.5 &#x000b5;g/g) resulted in the death of all NEMO<sup>f/f</sup> mice within 10 h (<xref ref-type="fig" rid="fig1">Fig. 1 A</xref>). Unexpectedly, NEMO<sup>&#x00394;hepa</sup> animals were less sensitive to Jo2, as 90% of the mice survived (<xref ref-type="fig" rid="fig1">Fig. 1 A</xref>). Macroscopic view confirmed that NEMO<sup>&#x00394;hepa</sup> livers remained unaffected while NEMO<sup>f/f</sup> showed significant blood accumulation and a higher liver weight/body weight ratio (<xref ref-type="fig" rid="fig1">Fig. 1 B</xref>). Accordingly, NEMO<sup>f/f</sup> mice showed clear signs of fulminant hepatitis, as high ALT levels, infiltrating PMN and RBC, necrosis, and apoptotic bodies were observed (<xref ref-type="fig" rid="fig1">Fig. 1, C and D</xref>). In contrast, we failed to detect any significant effects of Jo2 in NEMO<sup>&#x00394;hepa</sup> mice, as only the preexisting elevated ALT levels and parenchymal damage, caused by the spontaneous phenotype of these mice, was observed (<xref ref-type="fig" rid="fig1">Fig. 1, C and D</xref>). TUNEL assay, caspase 8, and caspase 3 activity confirmed resistance to Fas-induced apoptosis in NEMO<sup>&#x00394;hepa</sup> mice (<xref ref-type="fig" rid="fig1">Fig. 1, E and F</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><p><bold>Hepatocyte-specific NEMO-deleted mice (NEMO<sup>&#x00394;hepa</sup>) are protected against Fas-mediated apoptosis.</bold> (A) Survival curve after i.p. injection of 0.5 &#x000b5;g/g Jo2, evidencing the resistance of NEMO<sup>&#x00394;hepa</sup> mice to Fas-mediated death. (B&#x02013;D) Macroscopic view of livers 3 h after Jo2 (B), liver weight/body weight ratio (B), serum transaminases (C), and H&#x00026;E staining (D) showed fulminant hepatitis in NEMO<sup>f/f</sup> mice after Jo2, whereas NEMO<sup>&#x00394;hepa</sup> remained unaffected. (E and F) TUNEL (E) and caspase 8 and 3 (F) activity analysis confirmed Jo2 apoptosis. Activity is represented in times versus untreated NEMO<sup>f/f</sup>. (G and H) Fas mRNA and IHC analysis in whole liver (G) and isolated primary hepatocytes (H) showed stronger expression in WT compared than in NEMO<sup>&#x00394;hepa</sup> mice. (I) TNF mRNA and cellular location indicated by IHC. (J) Western blotting showed phosphorylation of JNK1 (p45) and JNK2 (p54) in NEMO<sup>f/f</sup> mice after Jo2. JNK1 and GAPDH act as loading controls. Bars, 50 &#x000b5;m. Data are representative of three independent experiments. <italic>n</italic> = 4. *, P &#x0003c; 0.05; **, P &#x0003c; 0.01; ***, P &#x0003c; 0.001 (NEMO<sup>f/f</sup> vs. NEMO<sup>&#x00394;hepa</sup>). &#x000a7;&#x000a7;, P &#x0003c; 0.01; &#x000a7;&#x000a7;&#x000a7;, P &#x0003c; 0.001 (NEMO<sup>f/f</sup> vs. Jo2/NEMO<sup>f/f</sup>). Error bars represent SD.</p></caption><graphic xlink:href="JEM_20082152_RGB_Fig1"/></fig><p>These data may seem contradictory to reports showing that NF-&#x003ba;B inhibition sensitizes hepatocytes to Fas apoptosis (<xref ref-type="bibr" rid="bib4">Hatano et al., 2000</xref>). However, as we previously described, NF-&#x003ba;B is one of the main factors responsible for activating <italic>Fas</italic> transcription (<xref ref-type="bibr" rid="bib9">Kuhnel et al., 2000</xref>). Thus, we hypothesized that NEMO<sup>&#x00394;hepa</sup> mice might have a defective turnover of this receptor, thereby promoting resistance to Jo2 apoptosis. In agreement with this, NEMO<sup>&#x00394;hepa</sup> mice exhibited reduced levels of Fas (25% less) and impaired up-regulation of Fas after Jo2 (<xref ref-type="fig" rid="fig1">Fig. 1 G</xref>). IHC confirmed these results, as Fas staining was almost negative on NEMO<sup>&#x00394;hepa</sup> mice after Jo2 (<xref ref-type="fig" rid="fig1">Fig. 1 G</xref>). Messenger RNA (mRNA) analysis on isolated primary hepatocytes corroborated the inability of NEMO<sup>&#x00394;hepa</sup> mice to express Fas (<xref ref-type="fig" rid="fig1">Fig. 1 H</xref>), which led to impaired NF-&#x003ba;B activation on these cells (not depicted).</p><p>Additionally, in accordance with the observation that Jo2/Fas induces TNF expression through NF-&#x003ba;B activation (<xref ref-type="bibr" rid="bib12">Lu et al., 2002</xref>), we found a strong up-regulation of TNF in NEMO<sup>f/f</sup> mice after Jo2 (43-fold), whereas it was barely regulated in NEMO<sup>&#x00394;hepa</sup> mice (<xref ref-type="fig" rid="fig1">Fig. 1 I</xref>). IHC on liver sections confirmed macrophages as the main source of TNF after Fas activation, which likely explains the modest TNF regulation observed in NEMO<sup>&#x00394;hepa</sup> mice (<xref ref-type="fig" rid="fig1">Fig. 1 I</xref>).</p><p>Finally, NEMO<sup>f/f</sup> mice displayed strong c-Jun N-terminal kinase (JNK) phosphorylation, whereas it remained inactive in NEMO<sup>&#x00394;hepa</sup> mice after Jo2 (<xref ref-type="fig" rid="fig1">Fig. 1 J</xref>), supporting the absence of cellular stress in our KO animals upon Fas activation. These results suggest that Fas is not an essential mediator of the pathogenesis observed in NEMO<sup>&#x00394;hepa</sup> mice.</p><p>Thus, we next investigated the potential implication of TRAIL in the initiation and progression of chronic liver damage in our NEMO-deficient mice. As expected, low doses of TRAIL had no effect on NEMO<sup>f/f</sup> mice, as ALT levels and liver architecture remained unaffected (<xref ref-type="fig" rid="fig2">Fig. 2, A and B</xref>). In clear contrast, TRAIL had a strong impact on NEMO<sup>&#x00394;hepa</sup> mice, as a significant rise in serum ALT and massive liver damage, indicated by profuse PMN infiltration, necrosis, and apoptosis, were observed (<xref ref-type="fig" rid="fig2">Fig. 2, A and B</xref>). TUNEL assay and caspase 3 activity confirmed the severity of TRAIL-mediated apoptosis on NEMO<sup>&#x00394;hepa</sup> mice (<xref ref-type="fig" rid="fig2">Fig. 2, C and D</xref>). Previous work indicated that TRAIL induced JNK activation, leading to cellular apoptosis (<xref ref-type="bibr" rid="bib5">Herr et al., 1999</xref>). Accordingly, we found that TRAIL promoted strong JNK activation in NEMO<sup>&#x00394;hepa</sup> livers, whereas it remained inactive in NEMO<sup>f/f</sup> mice (<xref ref-type="fig" rid="fig2">Fig. 2 E</xref>). Moreover, TRAIL administration promoted a significant induction of TNF in NEMO<sup>&#x00394;hepa</sup> mice that was confirmed by IHC, uncovering the Kupffer cells as its main source (<xref ref-type="fig" rid="fig2">Fig. 2 F</xref>). These results suggest that hepatocyte-NEMO deletion promotes hypersensitivity to TRAIL-mediated apoptosis; hence, we next attempted to elucidate the potential mechanisms underlying this effect.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><p><bold>NEMO<sup>&#x00394;hepa</sup> mice are sensitive to low doses of TRAIL-mediated liver injury.</bold> 25 mg/kg of flagged TRAIL was administered i.v. (A) ALT serum levels were significantly elevated in NEMO<sup>&#x00394;hepa</sup> mice after TRAIL. (B&#x02013;D) H&#x00026;E staining (B), TUNEL assay (C), and caspase 3 activity (D) showed TRAIL-mediated liver damage and apoptosis in NEMO<sup>&#x00394;hepa</sup> mice. (E) Western blot analysis showed JNK phosphorylation. JNK1 and GAPDH were used as loading controls. (F) RT-PCR analysis of TNF mRNA and IHC showed higher expression in NEMO<sup>&#x00394;hepa</sup> mice. (G) mRNA analysis and IHC evidenced strong DR5 expression in NEMO<sup>&#x00394;hepa</sup> livers compared with NEMO<sup>f/f</sup>. Bars, 50 &#x000b5;m. All data are representative of three independent experiments. <italic>n</italic> = 4. **, P &#x0003c; 0.01; ***, P &#x0003c; 0.001 (NEMO<sup>f/f</sup> vs. NEMO<sup>&#x00394;hepa</sup>). &#x000a7;&#x000a7;, P &#x0003c; 0.01; &#x000a7;&#x000a7;&#x000a7;, P &#x0003c; 0.001 (NEMO<sup>&#x00394;hepa</sup> vs. TRAIL/NEMO<sup>&#x00394;hepa</sup>). Error bars represent SD.</p></caption><graphic xlink:href="JEM_20082152_RGB_Fig2"/></fig><p>Interestingly, DR5 was highly expressed in livers of untreated NEMO<sup>&#x00394;hepa</sup> mice, where it was mainly present in hepatocytes (<xref ref-type="fig" rid="fig2">Fig. 2 G</xref>). This was confirmed in vitro, where NEMO<sup>&#x00394;hepa</sup> hepatocytes showed an eightfold increase in DR5 expression and a complete inability to activate NF-&#x003ba;B in response to TRAIL in contrast to WT cells (<ext-link ext-link-type="uri" xlink:href="http://www.jem.org/cgi/content/full/jem.20082152/DC1">Fig. S2, A and B</ext-link>). Accordingly with our in vivo data, WT cells remained unaffected, whereas TRAIL induced JNK activation on hepatocytes lacking NEMO, leading to strong apoptotic cell death which was significantly abrogated by JNK inhibition with SP600125 (Fig. S2, C and D). The protection elicited by JNK inhibition, despite the absence of NF-&#x003ba;B in NEMO-deficient hepatocytes, suggests an essential role of DR5-JNK signaling during TRAIL-induced cellular damage in NEMO<sup>&#x00394;hepa</sup> mice.</p><p>NK cells are the main producers of TRAIL in the liver (<xref ref-type="bibr" rid="bib22">Smyth et al., 2001</xref>; <xref ref-type="bibr" rid="bib23">Takeda et al., 2001</xref>). Earlier studies demonstrated that genetically or dietary-induced fatty liver disease promotes activation of these cells (<xref ref-type="bibr" rid="bib3">Guebre-Xabier et al., 2000</xref>; <xref ref-type="bibr" rid="bib10">Li et al., 2005</xref>). Thus, we hypothesized that similar alterations in the innate immune system might also arise in livers of NEMO<sup>&#x00394;hepa</sup> mice.</p><p>NEMO<sup>&#x00394;hepa</sup> livers had significantly reduced numbers of NK and NKT cells compared with NEMO<sup>f/f</sup> littermates (<xref ref-type="fig" rid="fig3">Fig. 3 A</xref>). As NK cells' activation is associated with their apoptosis, the lower NK1.1<sup>+</sup> cell number found in NEMO<sup>&#x00394;hepa</sup> livers could reflect their activation. Hence, NK1.1<sup>+</sup> cells from NEMO<sup>&#x00394;hepa</sup> mice exhibited significantly higher levels of annexin V when compared with NEMO<sup>f/f</sup> mice (<xref ref-type="fig" rid="fig3">Fig. 3 B</xref>). Activation of NK cells involves strong production of proinflammatory cytokines, like IFN-&#x003b3; and IL-12, promoting their cytotoxic activity and apoptosis (<xref ref-type="bibr" rid="bib28">Vivier et al., 2008</xref>). Accordingly, we found higher IFN-&#x003b3; and IL-12 (p35) expression associated with lower IL-4 levels in NEMO<sup>&#x00394;hepa</sup> mice compared with WT littermates. Additionally, higher CCL5 (RANTES) levels found in NEMO<sup>&#x00394;hepa</sup> livers (<xref ref-type="fig" rid="fig3">Fig. 3 C</xref>) may reflect a compensatory response to restore liver NK cells number (<xref ref-type="bibr" rid="bib17">Morris and Ley, 2004</xref>). These data were confirmed on isolated NK1.1<sup>+</sup> cells from livers of NEMO<sup>&#x00394;hepa</sup> mice showing higher IFN-&#x003b3; and CCL5 but lower IL4 levels (<xref ref-type="fig" rid="fig3">Fig. 3 D</xref>). FACS and mRNA analysis evidenced strong TRAIL expression on liver NK1.1<sup>+</sup> cells from NEMO<sup>&#x00394;hepa</sup> compared with WT mice (<xref ref-type="fig" rid="fig3">Fig. 3 E</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><p><bold>Hepatocyte-specific deletion of NEMO promotes spontaneous activation of liver NK/NKT cells, and administration of NK1.1-depleting mAb attenuates the damaging phenotype in NEMO<sup>&#x00394;hepa</sup> mice.</bold> (A) FACS analysis revealed a lower number of NK1.1<sup>+</sup>CD3<sup>&#x02212;</sup> and NK1.1<sup>+</sup>CD3<sup>+</sup> cells in NEMO<sup>&#x00394;hepa</sup> mice. The graph represents the percentage of NK1.1<sup>+</sup> cells related to the percentage of CD45<sup>+</sup> cells in the liver (B) FACS analysis of NK1.1<sup>+</sup>/annexin V<sup>+</sup> related to % of CD45<sup>+</sup> cells revealed strong apoptosis of NK1.1<sup>+</sup> cells in livers from NEMO<sup>&#x00394;hepa</sup> mice. (C) RT-PCR showed strong expression of IL-12 (p35), IFN-&#x003b3;, and CCL5 but lower IL-4 mRNA in livers. Data are presented as times versus NEMO<sup>f/f</sup> untreated. (D) mRNA analysis of isolated NK1.1<sup>+</sup> cells confirmed cell activation and increased cytokine expression. (E) FACS analysis showed stronger TRAIL expression on NK1.1<sup>+</sup> cells from livers from NEMO<sup>&#x00394;hepa</sup> mice. mRNA analysis on isolated NK1.1<sup>+</sup> cells confirmed this. (F and G) FACS analysis proved effective depletion of NK1.1<sup>+</sup> cells (F) 40 h after NK1.1 mAb administration that reduced IFN-&#x003b3; and CCL5 mRNA levels (G). (H&#x02013;J) Serum ALT (H), H&#x00026;E staining (I), and FACS analysis (J; CD11b<sup>+</sup> cells) were used as markers of liver damage and inflammation. Bars, 50 &#x000b5;m. All data are representative of three independent experiments. <italic>n</italic> = 4. *, P &#x0003c; 0.05; **, P &#x0003c; 0.01; ***, P &#x0003c; 0.001 (NEMO<sup>f/f</sup> vs. NEMO<sup>&#x00394;hepa</sup>). &#x000a7;&#x000a7;, P &#x0003c; 0.01 (NEMO<sup>&#x00394;hepa</sup> vs. Nk1.1mAb/NEMO<sup>&#x00394;hepa</sup>). Error bars represent SD.</p></caption><graphic xlink:href="JEM_20082152_RGB_Fig3"/></fig><p>These data suggest that hepatocyte-NEMO deletion correlates with an altered NK/NKT cell response. Moreover, the proclivity of TRAIL-producing NK cells to promote cytotoxicity against self-hepatocytes (<xref ref-type="bibr" rid="bib18">Ochi et al., 2004</xref>) appears to be enhanced in NEMO<sup>&#x00394;hepa</sup> mice, suggesting that this may represent a potential mechanism involved in the chronic inflammation and parenchymal damage observed in NEMO<sup>&#x00394;hepa</sup> mice.</p><p>To test this hypothesis, we investigated the potential beneficial effects of NK/NKT cell inactivation in NEMO<sup>&#x00394;hepa</sup> mice by using a NK1.1 mAb (PK-136). FACS and mRNA analysis confirmed efficient cell depletion after NK1.1 mAb administration (<xref ref-type="fig" rid="fig3">Fig. 3 F</xref>) that attenuated IFN-&#x003b3; and CCL5 expression, correlating with strong amelioration of liver damage in NEMO<sup>&#x00394;hepa</sup> mice (<xref ref-type="fig" rid="fig3">Fig. 3, H and I</xref>). FACS analysis confirmed the attenuation of the proinflammatory environment in NK1.1 mAb-treated NEMO<sup>&#x00394;hepa</sup> mice, as a significant reduction of CD11b<sup>+</sup> cells was detected (<xref ref-type="fig" rid="fig3">Fig. 3 J</xref>).</p><p>Based on our present data, which identify the critical detrimental role of NK1.1<sup>+</sup> cells in the pathogenesis of liver injury in NEMO<sup>&#x00394;hepa</sup> mice (<xref ref-type="fig" rid="fig3">Fig. 3</xref>), we further characterized the contribution of these cells during concanavalin A (ConA) hepatitis, where NKT cells activation have a major implication (<xref ref-type="bibr" rid="bib25">Toyabe et al., 1997</xref>; <xref ref-type="bibr" rid="bib24">Takeda et al., 2000</xref>).</p><p>Administration of 15 mg/kg ConA caused 100% mortality of NEMO<sup>&#x00394;hepa</sup> mice within 16 h, whereas all NEMO<sup>f/f</sup> mice survived (<ext-link ext-link-type="uri" xlink:href="http://www.jem.org/cgi/content/full/jem.20082152/DC1">Fig. S3</ext-link>). To better define the molecular mechanism leading to the mortality of NEMO<sup>&#x00394;hepa</sup> mice, we next administered 25 mg/kg ConA and sacrificed the animals 6 h after injection. ConA triggered a more severe hepatitis in NEMO<sup>&#x00394;hepa</sup> mice compared to NEMO<sup>f/f</sup> littermates. Massive destruction of liver parenchyma in NEMO<sup>&#x00394;hepa</sup> mice were indicated by high ALT, strong inflammation, and necrotic and apoptotic cell death (<xref ref-type="fig" rid="fig4">Fig. 4, A&#x02013;C</xref>). Moreover, ConA induced significantly higher levels of IFN-&#x003b3;, IL-4, and CCL5 in NEMO<sup>&#x00394;hepa</sup> compared with NEMO<sup>f/f</sup> livers (<xref ref-type="fig" rid="fig4">Fig. 4 D</xref>). ELISA confirmed systemic IFN-&#x003b3; elevation (<xref ref-type="fig" rid="fig4">Fig. 4 E</xref>).</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><p><bold>ConA promotes stronger liver damage in NEMO<sup>&#x00394;hepa</sup> mice than in NEMO<sup>f/f</sup> animals.</bold> (A&#x02013;C) ALT serum levels (A), H&#x00026;E staining and TUNEL analysis (B), and quantification of caspase 8 and 3 activity (C) measured 6 h after 25 mg/kg ConA showed strong liver damage in NEMO<sup>&#x00394;hepa</sup> mice. (D) mRNA levels of IFN-&#x003b3;, IL-4, CCL5, IL-12p35, TNF, and IL-10. All RT-PCR data are presented as times versus NEMO<sup>f/f</sup> untreated. (E) ELISA of IFN-&#x003b3; and TNF in serum before and 6 h after 25 mg/kg ConA. Bars, 50 &#x000b5;m. All data are representative of three independent experiments. <italic>n</italic> = 4. *, P &#x0003c; 0.05; **, P &#x0003c; 0.01; ***, P &#x0003c; 0.001 (NEMO<sup>f/f</sup> vs. NEMO<sup>&#x00394;hepa</sup>). &#x000a7;&#x000a7;, P &#x0003c; 0.01; &#x000a7;&#x000a7;&#x000a7;, P &#x0003c; 0.001 (NEMO<sup>&#x00394;hepa</sup> vs. ConA/NEMO<sup>&#x00394;hepa</sup>). Error bars represent SD.</p></caption><graphic xlink:href="JEM_20082152_RGB_Fig4"/></fig><p>Activated macrophages are the main producers of IL-12, which promotes NKT cell activation and further IFN-&#x003b3; production (<xref ref-type="bibr" rid="bib27">Trinchieri, 2003</xref>). This phenomenon may also occur in NEMO<sup>&#x00394;hepa</sup> mice, as IL12-p35 was significantly upregulated before ConA and was further increased following injury (<xref ref-type="fig" rid="fig4">Fig. 4 D</xref>).</p><p>Expression of the antiinflammatory cytokine IL-10, which negatively regulates TNF, IFN-&#x003b3;, and IL-12 after ConA (<xref ref-type="bibr" rid="bib11">Louis et al., 1997</xref>), was significantly lower in NEMO<sup>&#x00394;hepa</sup>, indicating their inability to orchestrate a proper antiinflammatory response to ConA hepatitis (<xref ref-type="fig" rid="fig4">Fig. 4 D</xref>). As expected, up-regulation of TNF was observed in WT and NEMO<sup>&#x00394;hepa</sup> mice after ConA but no significant differences were observed between genotypes (<xref ref-type="fig" rid="fig4">Fig. 4, D and E</xref>).</p><p>NK/NKT cell depletion lead to a remarkable improvement of liver parenchyma, indicated by lower ALT, necrosis, inflammation, and infiltration of PMNs (<xref ref-type="fig" rid="fig5">Fig. 5, A and B</xref>). Attenuation of ConA induced liver apoptosis after NK1.1 mAb treatment was confirmed by TUNEL assay and caspase 8 activity (<xref ref-type="fig" rid="fig5">Fig. 5 C</xref>). Accordingly, IFN-&#x003b3;, CCL5, and IL-4 levels were lower after ConA in NK1.1-depleted NEMO<sup>&#x00394;hepa</sup> mice (<xref ref-type="fig" rid="fig5">Fig. 5 D</xref>), and systemic IFN-&#x003b3; and TNF serum levels were significantly reduced (<xref ref-type="fig" rid="fig5">Fig. 5 E</xref>). Remnant cytokine expression despite NK1.1 mAb is likely explained by the fact that ConA promotes activation of other cell compartments like macrophages.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><p><bold>NK1.1 cell depletion and adoptive transfer of TRAIL<sup>&#x02212;/&#x02212;</sup> MNCs protects NEMO<sup>&#x00394;hepa</sup> mice against ConA-mediated fulminant hepatitis.</bold> (A&#x02013;C) ALT serum levels (A), H&#x00026;E staining (B), TUNEL analysis, and quantification of caspase 8 (C), 6 h after 25 mg/kg ConA revealed strong attenuation of ConA hepatitis in NEMO<sup>&#x00394;hepa</sup> mice when NK1.1 mAb was administered 40 h before insult. (D and E) mRNA levels of IFN-&#x003b3;, CCL5, and IL-4 (D) and ELISA of IFN-&#x003b3; and TNF (E) on serum confirmed attenuation of ConA damage in NEMO<sup>&#x00394;hepa</sup> mice after NK1.1 mAb. (F&#x02013;H) Adoptive transfer of TRAIL<sup>&#x02212;/&#x02212;</sup> MNCs and liver TRAIL<sup>&#x02212;/&#x02212;</sup> NK1.1<sup>+</sup> cells after NK1.1 mAb protected while TRAIL<sup>+/+</sup> MNC transfer restored ConA injury in NEMO<sup>&#x00394;hepa</sup> mice as shown by serum ALT (F), H&#x00026;E staining (G), and ELISA (H) of IFN-&#x003b3; serum levels. (I) ConA-mediated JNK activation was attenuated by NK1.1 mAb and restored by TRAIL<sup>+/+</sup> MNCs adoptive transfer. TRAIL<sup>&#x02212;/&#x02212;</sup> cells maintained JNK inactivated. JNK1 and GAPDH act as loading control. Bars, 50 &#x000b5;m. All data are representative of three independent experiments. <italic>n</italic> = 4. **, P &#x0003c; 0.01; ***, P &#x0003c; 0.001 (NEMO<sup>&#x00394;hepa</sup> vs. ConA/NEMO<sup>&#x00394;hepa</sup>). &#x000a7;, P &#x0003c; 0.05; &#x000a7;&#x000a7;, P &#x0003c; 0.01; &#x000a7;&#x000a7;&#x000a7;, P &#x0003c; 0.001 (ConA/NEMO<sup>&#x00394;hepa</sup> vs. NK1.1mAb/ConA/NEMO<sup>&#x00394;hepa</sup>).</p></caption><graphic xlink:href="JEM_20082152_RGB_Fig5"/></fig><p>Recent work showing that TRAIL<sup>&#x02212;/&#x02212;</sup> mice are protected from ConA-induced liver injury highlighted the important role of TRAIL in this model (<xref ref-type="bibr" rid="bib29">Zheng et al., 2004</xref>). Thus, we examined if this cytokine may be an essential mediator of ConA liver damage in our NEMO<sup>&#x00394;hepa</sup> mice. We performed intrahepatic adoptive transfer of splenic mononuclear cells (MNCs) from TRAIL<sup>&#x02212;/&#x02212;</sup> or TRAIL<sup>+/+</sup> mice before ConA administration in NK1.1<sup>+</sup>-depleted mice. Liver damage was strongly attenuated in NEMO<sup>&#x00394;hepa</sup> mice receiving TRAIL<sup>&#x02212;/&#x02212;</sup> MNCs in contrast to TRAIL<sup>+/+</sup> MNC transferred mice, where injury was restored (<xref ref-type="fig" rid="fig5">Fig. 5, F and G</xref>). Additionally, adoptive transfer of TRAIL<sup>+/+</sup> MNCs into NK1.1-depleted NEMO<sup>&#x00394;hepa</sup> mice restored both liver and systemic IFN-&#x003b3; expression after ConA, whereas it remained low in NEMO<sup>&#x00394;hepa</sup> mice receiving TRAIL<sup>&#x02212;/&#x02212;</sup> MNCs (<xref ref-type="fig" rid="fig5">Fig. 5 H</xref>). The essential implication of NK cell&#x02013;derived TRAIL in mediating ConA hepatitis in NEMO<sup>&#x00394;hepa</sup> mice was further confirmed by adoptive transfer of isolated NK1.1<sup>+</sup> cells from TRAIL<sup>&#x02212;/&#x02212;</sup> mice, which preserved liver protection against ConA injury elicited by NK1.1 mAb (<xref ref-type="fig" rid="fig5">Fig. 5, F&#x02013;H</xref>).</p><p>During ConA-mediated hepatitis, JNK activation is related to the degree of apoptosis and the severity of the cellular stress (<xref ref-type="bibr" rid="bib26">Trautwein et al., 1998</xref>). Additionally, we showed the detrimental effects of the TRAIL-JNK cascade in NEMO<sup>&#x00394;hepa</sup> mice both in vivo and in vitro (<xref ref-type="fig" rid="fig2">Fig. 2</xref> and Fig. S2). Accordingly, strong JNK activation was observed in NEMO<sup>&#x00394;hepa</sup> mice after ConA, whereas it was clearly blunted after NK1.1 mAb despite ConA administration (<xref ref-type="fig" rid="fig5">Fig. 5 I</xref>). JNK activation was restored after adoptive transfer of TRAIL<sup>+/+</sup> MNCs in NEMO<sup>&#x00394;hepa</sup> livers after ConA despite NK1.1 mAb treatment. On the contrary, transfer of both TRAIL<sup>&#x02212;/&#x02212;</sup> MNCs and TRAIL<sup>&#x02212;/&#x02212;</sup> NK1.1<sup>+</sup> cells maintained the resistance of NK1.1-depleted NEMO<sup>&#x00394;hepa</sup> mice to ConA-mediated JNK activation (<xref ref-type="fig" rid="fig5">Fig. 5 I</xref>).</p><p>Previous studies using a NK1.1 mAb described that NKT cells are an essential cell subset responsible for ConA-mediated liver injury as selective depletion of NK cells with an anti-asialo GM1 antibody had no impact on ConA hepatitis (<xref ref-type="bibr" rid="bib25">Toyabe et al., 1997</xref>). However, our present data strongly support the hypothesis that NK cell&#x02013;derived TRAIL plays a key role in the progression of ConA-induced liver damage in NEMO<sup>&#x00394;hepa</sup> mice. Accordingly, we observed that NK cell depletion with asialo-GM1 mAb significantly reduced ALT levels (2.17-fold; <ext-link ext-link-type="uri" xlink:href="http://www.jem.org/cgi/content/full/jem.20082152/DC1">Fig. S4 A</ext-link>), a comparable effect to that observed with NK1.1 mAb (<xref ref-type="fig" rid="fig5">Fig. 5 A</xref>; 2.56-fold reduction). Accordingly, hematoxylin and eosin (H&#x00026;E) and TUNEL assay revealed significant protection against ConA after NK cell depletion (Fig. S4, B and C), accompanied by reduced CCL5 in asialo-GM1&#x02013;treated NEMO<sup>&#x00394;hepa</sup> mice. Interestingly, despite the clear protection elicited by NK cell depletion, we found high IL-4 mRNA expression in asialo-GM1 mAb&#x02013;treated KOs (Fig. S4 D) suggesting remnant activation of NKT cells. Moreover, downregulation of serum IFN-&#x003b3; levels supports the implication of this cytokine in the activation and production of TRAIL from NK cells in an autocrine fashion (<xref ref-type="bibr" rid="bib22">Smyth et al., 2001</xref>; <xref ref-type="bibr" rid="bib23">Takeda et al., 2001</xref>). This data strongly supports the essential role of TRAIL-producing NK cells in mediating the dramatic impact of ConA on NEMO<sup>&#x00394;hepa</sup> mice.</p><p>Our present study uncovers a new mechanism by which hepatocyte-specific NEMO deletion contributes to spontaneous liver inflammation and injury. We show that NEMO deletion sensitizes the liver to TRAIL-mediated apoptosis and this contributes to disease progression. We propose a dual mechanism consisting of up-regulation of DR5 on hepatocytes and the activation of TRAIL-producing NK cells to cause the detrimental effects of NEMO deletion in the liver. The first mechanism is supported by studies showing that steatosis and free fatty acids promote up-regulation of DR5 mRNA expression (<xref ref-type="bibr" rid="bib16">Malhi et al., 2007</xref>). Additionally, the profuse bile acid accumulation found in livers of NEMO<sup>&#x00394;hepa</sup> mice (unpublished data) may further promote DR5 expression (<xref ref-type="bibr" rid="bib7">Higuchi et al., 2004</xref>). In addition to increased DR5 expression, fatty liver disease also triggers NKT cell activation, leading to a proinflammatory cytokine response (<xref ref-type="bibr" rid="bib10">Li et al., 2005</xref>), which we also observed in our NEMO<sup>&#x00394;hepa</sup> mice.</p><p>Additionally, it has been shown that NKT cells promote NK cell activation and TRAIL production through IFN-&#x003b3; expression (<xref ref-type="bibr" rid="bib22">Smyth et al., 2001</xref>). At present, the relevance of intestinal bacterial products transported into the liver through the blood stream and its role in NK and NKT cell activation is unclear in this model. However, this mechanism could also be relevant, as LPS induces macrophages to produce IL-12, triggering IFN-&#x003b3; production by NKT cells in the absence of IL-4 (<xref ref-type="bibr" rid="bib1">Dobashi et al., 1999</xref>; <xref ref-type="bibr" rid="bib3">Guebre-Xabier et al., 2000</xref>). This scenario closely resembles the liver environment found in untreated NEMO<sup>&#x00394;hepa</sup> mice.</p><p>Our present work strengthens the essential role of hepatocyte NEMO/NF-&#x003ba;B to maintain liver homeostasis because absence of NEMO in these cells activates the innate immune system, thus promoting liver damage. The cascade of molecular events leading from steatohepatitis to fibrosis and tumor development observed in NEMO<sup>&#x00394;hepa</sup> mice reflects the pathogenesis of liver cirrhosis and HCC in humans. Further work in this model could yield novel therapeutic strategies targeting the NK cell/TRAIL axis to modulate chronic liver disease progression.</p></sec><sec sec-type="materials|methods"><title>MATERIALS AND METHODS</title><sec><title/><sec><title>Generation of hepatocyte-specific conditional NEMO KO mice.</title><p>We generated mice carrying the loxP site&#x02013;flanked (floxed [f]) <italic>NEMO</italic> gene (NEMO<sup>f/f</sup>) as described in detail in the supplemental figures. We generated NEMO<sup>&#x00394;hepa</sup> mice by crossing NEMO<sup>f/f</sup> with alfp-cre transgenic animals. For the experiments described, we used 8-wk-old male (Jo2 and TRAIL [provided by S. Bronk, Mayo Clinic College of Medicine, Rochester, MN) and female (NK1.1 mAb and ConA) mice. Animals were treated according to the guidelines of the National Academy of Sciences (National Institutes of Health publication 86-23, revised 1985). Animal husbandry and procedures were approved by the authority for environment conservation and consumer protection of the state North Rhine&#x02013;Westfalia (LANUV) and the University Hospital Aachen Animal Care Facility's guidelines.</p></sec><sec><title>Models of liver injury.</title><p>Jo2 (0.5 &#x000b5;g/g of body weight; BD) was injected i.p. and mice were sacrificed 3 h later. ConA (Sigma-Aldrich) was administered i.v. for either 6 h (15 mg/kg of body weight) or 24 h (25 mg/kg). Flagged TRAIL (<xref ref-type="bibr" rid="bib6">Higuchi et al., 2002</xref>) was administered i.v. at a concentration of 25 mg/kg.</p></sec><sec><title>Analysis of gene and serum protein expression.</title><p>RNA was isolated with PeqGold-RNA pure kit (PEQLAB) from livers. Quantitative real-time PCR was performed using SYBR green reagent (Invitrogen) in a 7300 Real-Time PCR system (Applied Biosystems). GAPDH was used to normalize gene expression, which is represented as times versus NEMO<sup>f/f</sup> basal expression. Liver and serum TNF and serum IFN-&#x003b3; levels were quantified by ELISA (R&#x00026;D systems and BD, respectively).</p></sec><sec><title>Western blotting.</title><p>Immunoblotting on liver protein extracts were performed with IKK&#x003b3;/NEMO, p65, and JNK1 (Santa Cruz Biotechnology Inc.), phospho-JNK1/JNK2 (Tyr183/185; Invitrogen), and GAPDH antibody (Biogenesis).</p></sec><sec><title>Histological evaluation and apoptosis determination.</title><p>H&#x00026;E staining was performed on paraffin-embedded liver sections. Apoptosis was evaluated by TUNEL assay performed on frozen liver sections using the in situ cell death detection kit (Roche) according to manufacturer's instructions. Caspase 8 and 3 activity were quantified on liver protein extracts as previously described (<xref ref-type="bibr" rid="bib13">Luedde et al., 2007</xref>). DR5 detection on liver sections was performed by IHC using a DR5 antibody (ProScience), followed by Cy-3&#x02013;labeled secondary antibody (Jackson ImmunoResearch Laboratories) or by the polyclonal Enhanced Vision reaction (Dako). TNF IHC was performed on frozen sections using rabbit polyclonal antibody (Santa Cruz Biotechnology, Inc.).</p></sec><sec><title>NK1.1<sup>+</sup> cell depletion.</title><p>NK1.1 antibody (250 &#x000b5;g/mouse i.p.) was purified from hybridoma PK-136 (American Type Culture Collection) culture supernatants. Depletion efficiency was determined by FACS analysis 40 h after administration. NK cell&#x02013;specific depletion was obtained by i.p. administration of 250 &#x000b5;g Asialo-GM1 mAb (Wako Chemicals USA, Inc.) per mouse.</p></sec><sec><title>MNC isolation, adoptive transfer, and flow cytometric analysis.</title><p>Liver and splenic MNCs were obtained as previously described (<xref ref-type="bibr" rid="bib29">Zheng et al., 2004</xref>) with small modifications. In brief, MNCs were isolated by collagenase digestion and erythrocytes were removed using PharmLyse lysing buffer (BD). MNCs were purified by density gradient centrifugation using Lymphocyte (LSM 1077; PAA). 2 &#x000d7; 10<sup>7</sup> splenic MNCs were injected in the lateral left liver lobe of NEMO<sup>&#x00394;hepa</sup> mice using a 29-gauge needle 1 h before i.v. administration of 25 mg/kg ConA.</p></sec><sec><title>Flow cytometry analysis and cell sorting.</title><p>Cells were stained with CD45-APC-Cy7, NK1.1-PE-Cy7, CD11b-PE, annexin V&#x02013;FITC (BD), and CD3-APC (eBioscience). All samples were analyzed by flow cytometry (FACS Canto II; BD). For NK cell isolation, livers cells were isolated, stained, and purified by high speed sorting using a FACSAria (BD). CD45<sup>+</sup>NK1.1<sup>+</sup> cells were further analyzed or transferred into animals while CD45<sup>+</sup>CD19<sup>+</sup> cells were discarded. Purity of isolated NK1.1<sup>+</sup> cells was &#x0003e;98%.</p></sec><sec><title>Statistical analysis.</title><p>Data are expressed as mean &#x000b1; standard deviation of the mean. Statistical significance was determined by two-way analysis of variance followed by a Student's <italic>t</italic> test.</p></sec><sec><title>Online supplemental material.</title><p>Fig. S1 shows the gene-targeting strategy for the generation of hepatocyte-specific NEMO KO mice. Fig. S2 demonstrates the effect of TRAIL on primary hepatocytes. Fig. S3 shows the survival curve after ConA treatment. Fig. S4 shows the effects of asialo-GM1 mAb administration during ConA hepatitis. Online supplemental material is available at <ext-link ext-link-type="uri" xlink:href="http://www.jem.org/cgi/content/full/jem.20082152/DC1">http://www.jem.org/cgi/content/full/jem.20082152/DC1</ext-link>.</p></sec></sec></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="PMC_1" content-type="local-data"><caption><title>[Supplemental Material]</title></caption><media mimetype="text" mime-subtype="html" xlink:href="jem.20082152_index.html"/><media xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="jem.20082152_1.pdf"/></supplementary-material></sec></body><back><ack><p>We want to thank Steve Bronk for providing us with the TRAIL protein. We also want to thank Sara Dutton Sackett for editing the manuscript.</p><p>This work was supported by the SFB542, C15.</p><p>The authors declare that they have no competing financial interests.</p></ack><ref-list><ref id="bib2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beraza</surname><given-names>N.</given-names></name><name><surname>Luedde</surname><given-names>T.</given-names></name><name><surname>Assmus</surname><given-names>U.</given-names></name><name><surname>Roskams</surname><given-names>T.</given-names></name><name><surname>Vander Borght</surname><given-names>S.</given-names></name><name><surname>Trautwein</surname><given-names>C.</given-names></name></person-group><year>2007</year><article-title>Hepatocyte-specific IKK gamma/NEMO expression determines the degree of liver injury</article-title>.<source>Gastroenterology</source><volume>132</volume>:<fpage>2504</fpage>&#x02013;<lpage>2517</lpage><pub-id pub-id-type="pmid">17570222</pub-id></mixed-citation></ref><ref id="bib1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobashi</surname><given-names>H.</given-names></name><name><surname>Seki</surname><given-names>S.</given-names></name><name><surname>Habu</surname><given-names>Y.</given-names></name><name><surname>Ohkawa</surname><given-names>T.</given-names></name><name><surname>Takeshita</surname><given-names>S.</given-names></name><name><surname>Hiraide</surname><given-names>H.</given-names></name><name><surname>Sekine</surname><given-names>I.</given-names></name></person-group><year>1999</year><article-title>Activation of mouse liver natural killer cells and NK1.1(+) T cells by bacterial superantigen-primed Kupffer cells</article-title>.<source>Hepatology.</source><volume>30</volume>:<fpage>430</fpage>&#x02013;<lpage>436</lpage><pub-id pub-id-type="pmid">10421651</pub-id></mixed-citation></ref><ref id="bib3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guebre-Xabier</surname><given-names>M.</given-names></name><name><surname>Yang</surname><given-names>S.</given-names></name><name><surname>Lin</surname><given-names>H.Z.</given-names></name><name><surname>Schwenk</surname><given-names>R.</given-names></name><name><surname>Krzych</surname><given-names>U.</given-names></name><name><surname>Diehl</surname><given-names>A.M.</given-names></name></person-group><year>2000</year><article-title>Altered hepatic lymphocyte subpopulations in obesity-related murine fatty livers: potential mechanism for sensitization to liver damage</article-title>.<source>Hepatology.</source><volume>31</volume>:<fpage>633</fpage>&#x02013;<lpage>640</lpage><pub-id pub-id-type="pmid">10706553</pub-id></mixed-citation></ref><ref id="bib4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatano</surname><given-names>E.</given-names></name><name><surname>Bradham</surname><given-names>C.A.</given-names></name><name><surname>Stark</surname><given-names>A.</given-names></name><name><surname>Iimuro</surname><given-names>Y.</given-names></name><name><surname>Lemasters</surname><given-names>J.J.</given-names></name><name><surname>Brenner</surname><given-names>D.A.</given-names></name></person-group><year>2000</year><article-title>The mitochondrial permeability transition augments Fas-induced apoptosis in mouse hepatocytes</article-title>.<source>J. Biol. Chem.</source><volume>275</volume>:<fpage>11814</fpage>&#x02013;<lpage>11823</lpage><pub-id pub-id-type="pmid">10766806</pub-id></mixed-citation></ref><ref id="bib5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herr</surname><given-names>I.</given-names></name><name><surname>Wilhelm</surname><given-names>D.</given-names></name><name><surname>Meyer</surname><given-names>E.</given-names></name><name><surname>Jeremias</surname><given-names>I.</given-names></name><name><surname>Angel</surname><given-names>P.</given-names></name><name><surname>Debatin</surname><given-names>K.M.</given-names></name></person-group><year>1999</year><article-title>JNK/SAPK activity contributes to TRAIL-induced apoptosis</article-title>.<source>Cell Death Differ.</source><volume>6</volume>:<fpage>130</fpage>&#x02013;<lpage>135</lpage><pub-id pub-id-type="pmid">10200559</pub-id></mixed-citation></ref><ref id="bib6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higuchi</surname><given-names>H.</given-names></name><name><surname>Bronk</surname><given-names>S.F.</given-names></name><name><surname>Taniai</surname><given-names>M.</given-names></name><name><surname>Canbay</surname><given-names>A.</given-names></name><name><surname>Gores</surname><given-names>G.J.</given-names></name></person-group><year>2002</year><article-title>Cholestasis increases tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-R2/DR5 expression and sensitizes the liver to TRAIL-mediated cytotoxicity</article-title>.<source>J. Pharmacol. Exp. Ther.</source><volume>303</volume>:<fpage>461</fpage>&#x02013;<lpage>467</lpage><pub-id pub-id-type="pmid">12388624</pub-id></mixed-citation></ref><ref id="bib7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higuchi</surname><given-names>H.</given-names></name><name><surname>Grambihler</surname><given-names>A.</given-names></name><name><surname>Canbay</surname><given-names>A.</given-names></name><name><surname>Bronk</surname><given-names>S.F.</given-names></name><name><surname>Gores</surname><given-names>G.J.</given-names></name></person-group><year>2004</year><article-title>Bile acids up-regulate death receptor 5/TRAIL-receptor 2 expression via a c-Jun N-terminal kinase-dependent pathway involving Sp1</article-title>.<source>J. Biol. Chem.</source><volume>279</volume>:<fpage>51</fpage>&#x02013;<lpage>60</lpage><pub-id pub-id-type="pmid">14561739</pub-id></mixed-citation></ref><ref id="bib8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kellendonk</surname><given-names>C.</given-names></name><name><surname>Opherk</surname><given-names>C.</given-names></name><name><surname>Anlag</surname><given-names>K.</given-names></name><name><surname>Schutz</surname><given-names>G.</given-names></name><name><surname>Tronche</surname><given-names>F.</given-names></name></person-group><year>2000</year><article-title>Hepatocyte-specific expression of Cre recombinase</article-title>.<source>Genesis.</source><volume>26</volume>:<fpage>151</fpage>&#x02013;<lpage>153</lpage><pub-id pub-id-type="pmid">10686615</pub-id></mixed-citation></ref><ref id="bib9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhnel</surname><given-names>F.</given-names></name><name><surname>Zender</surname><given-names>L.</given-names></name><name><surname>Paul</surname><given-names>Y.</given-names></name><name><surname>Tietze</surname><given-names>M.K.</given-names></name><name><surname>Trautwein</surname><given-names>C.</given-names></name><name><surname>Manns</surname><given-names>M.</given-names></name><name><surname>Kubicka</surname><given-names>S.</given-names></name></person-group><year>2000</year><article-title>NFkappaB mediates apoptosis through transcriptional activation of Fas (CD95) in adenoviral hepatitis</article-title>.<source>J. Biol. Chem.</source><volume>275</volume>:<fpage>6421</fpage>&#x02013;<lpage>6427</lpage><pub-id pub-id-type="pmid">10692445</pub-id></mixed-citation></ref><ref id="bib10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Soloski</surname><given-names>M.J.</given-names></name><name><surname>Diehl</surname><given-names>A.M.</given-names></name></person-group><year>2005</year><article-title>Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease</article-title>.<source>Hepatology.</source><volume>42</volume>:<fpage>880</fpage>&#x02013;<lpage>885</lpage><pub-id pub-id-type="pmid">16175608</pub-id></mixed-citation></ref><ref id="bib11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Louis</surname><given-names>H.</given-names></name><name><surname>Le Moine</surname><given-names>O.</given-names></name><name><surname>Peny</surname><given-names>M.O.</given-names></name><name><surname>Quertinmont</surname><given-names>E.</given-names></name><name><surname>Fokan</surname><given-names>D.</given-names></name><name><surname>Goldman</surname><given-names>M.</given-names></name><name><surname>Deviere</surname><given-names>J.</given-names></name></person-group><year>1997</year><article-title>Production and role of interleukin-10 in concanavalin A-induced hepatitis in mice</article-title>.<source>Hepatology.</source><volume>25</volume>:<fpage>1382</fpage>&#x02013;<lpage>1389</lpage><pub-id pub-id-type="pmid">9185757</pub-id></mixed-citation></ref><ref id="bib12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Medan</surname><given-names>D.</given-names></name><name><surname>Toledo</surname><given-names>D.</given-names></name><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>F.</given-names></name><name><surname>Shi</surname><given-names>X.</given-names></name><name><surname>Rojanasakul</surname><given-names>Y.</given-names></name></person-group><year>2002</year><article-title>Regulation of Fas (CD95)-induced apoptosis by nuclear factor-kappaB and tumor necrosis factor-alpha in macrophages</article-title>.<source>Am. J. Physiol. Cell Physiol.</source><volume>283</volume>:<fpage>C831</fpage>&#x02013;<lpage>C838</lpage><pub-id pub-id-type="pmid">12176740</pub-id></mixed-citation></ref><ref id="bib13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luedde</surname><given-names>T.</given-names></name><name><surname>Beraza</surname><given-names>N.</given-names></name><name><surname>Kotsikoris</surname><given-names>V.</given-names></name><name><surname>Van Loo</surname><given-names>G.</given-names></name><name><surname>Nenci</surname><given-names>A.</given-names></name><name><surname>De Vos</surname><given-names>R.</given-names></name><name><surname>Roskams</surname><given-names>T.</given-names></name><name><surname>Trautwein</surname><given-names>C.</given-names></name><name><surname>Pasparakis</surname><given-names>M.</given-names></name></person-group><year>2007</year><article-title>Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma</article-title>.<source>Cancer Cell.</source><volume>11</volume>:<fpage>119</fpage>&#x02013;<lpage>132</lpage><pub-id pub-id-type="pmid">17292824</pub-id></mixed-citation></ref><ref id="bib15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>J.L.</given-names></name><name><surname>Maeda</surname><given-names>S.</given-names></name><name><surname>Hsu</surname><given-names>L.C.</given-names></name><name><surname>Yagita</surname><given-names>H.</given-names></name><name><surname>Karin</surname><given-names>M.</given-names></name></person-group><year>2004</year><article-title>Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression</article-title>.<source>Cancer Cell.</source><volume>6</volume>:<fpage>297</fpage>&#x02013;<lpage>305</lpage><pub-id pub-id-type="pmid">15380520</pub-id></mixed-citation></ref><ref id="bib14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>J.L.</given-names></name><name><surname>Kamata</surname><given-names>H.</given-names></name><name><surname>Karin</surname><given-names>M.</given-names></name></person-group><year>2005</year><article-title>IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy</article-title>.<source>J. Clin. Invest.</source><volume>115</volume>:<fpage>2625</fpage>&#x02013;<lpage>2632</lpage><pub-id pub-id-type="pmid">16200195</pub-id></mixed-citation></ref><ref id="bib16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malhi</surname><given-names>H.</given-names></name><name><surname>Barreyro</surname><given-names>F.J.</given-names></name><name><surname>Isomoto</surname><given-names>H.</given-names></name><name><surname>Bronk</surname><given-names>S.F.</given-names></name><name><surname>Gores</surname><given-names>G.J.</given-names></name></person-group><year>2007</year><article-title>Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity</article-title>.<source>Gut.</source><volume>56</volume>:<fpage>1124</fpage>&#x02013;<lpage>1131</lpage><pub-id pub-id-type="pmid">17470478</pub-id></mixed-citation></ref><ref id="bib17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>M.A.</given-names></name><name><surname>Ley</surname><given-names>K.</given-names></name></person-group><year>2004</year><article-title>Trafficking of natural killer cells</article-title>.<source>Curr. Mol. Med.</source><volume>4</volume>:<fpage>431</fpage>&#x02013;<lpage>438</lpage><pub-id pub-id-type="pmid">15354873</pub-id></mixed-citation></ref><ref id="bib18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ochi</surname><given-names>M.</given-names></name><name><surname>Ohdan</surname><given-names>H.</given-names></name><name><surname>Mitsuta</surname><given-names>H.</given-names></name><name><surname>Onoe</surname><given-names>T.</given-names></name><name><surname>Tokita</surname><given-names>D.</given-names></name><name><surname>Hara</surname><given-names>H.</given-names></name><name><surname>Ishiyama</surname><given-names>K.</given-names></name><name><surname>Zhou</surname><given-names>W.</given-names></name><name><surname>Tanaka</surname><given-names>Y.</given-names></name><name><surname>Asahara</surname><given-names>T.</given-names></name></person-group><year>2004</year><article-title>Liver NK cells expressing TRAIL are toxic against self hepatocytes in mice</article-title>.<source>Hepatology.</source><volume>39</volume>:<fpage>1321</fpage>&#x02013;<lpage>1331</lpage><pub-id pub-id-type="pmid">15122761</pub-id></mixed-citation></ref><ref id="bib19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogasawara</surname><given-names>J.</given-names></name><name><surname>Watanabe-Fukunaga</surname><given-names>R.</given-names></name><name><surname>Adachi</surname><given-names>M.</given-names></name><name><surname>Matsuzawa</surname><given-names>A.</given-names></name><name><surname>Kasugai</surname><given-names>T.</given-names></name><name><surname>Kitamura</surname><given-names>Y.</given-names></name><name><surname>Itoh</surname><given-names>N.</given-names></name><name><surname>Suda</surname><given-names>T.</given-names></name><name><surname>Nagata</surname><given-names>S.</given-names></name></person-group><year>1993</year><article-title>Lethal effect of the anti-Fas antibody in mice</article-title>.<source>Nature.</source><volume>364</volume>:<fpage>806</fpage>&#x02013;<lpage>809</lpage><pub-id pub-id-type="pmid">7689176</pub-id></mixed-citation></ref><ref id="bib20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez</surname><given-names>C.I.</given-names></name><name><surname>Buchholz</surname><given-names>F.</given-names></name><name><surname>Galloway</surname><given-names>J.</given-names></name><name><surname>Sequerra</surname><given-names>R.</given-names></name><name><surname>Kasper</surname><given-names>J.</given-names></name><name><surname>Ayala</surname><given-names>R.</given-names></name><name><surname>Stewart</surname><given-names>A.F.</given-names></name><name><surname>Dymecki</surname><given-names>S.M.</given-names></name></person-group><year>2000</year><article-title>High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP</article-title>.<source>Nat. Genet.</source><volume>25</volume>:<fpage>139</fpage>&#x02013;<lpage>140</lpage><pub-id pub-id-type="pmid">10835623</pub-id></mixed-citation></ref><ref id="bib21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schutze</surname><given-names>S.</given-names></name><name><surname>Tchikov</surname><given-names>V.</given-names></name><name><surname>Schneider-Brachert</surname><given-names>W.</given-names></name></person-group><year>2008</year><article-title>Regulation of TNFR1 and CD95 signalling by receptor compartmentalization</article-title>.<source>Nat. Rev. Mol. Cell Biol.</source><volume>9</volume>:<fpage>655</fpage>&#x02013;<lpage>662</lpage><pub-id pub-id-type="pmid">18545270</pub-id></mixed-citation></ref><ref id="bib22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smyth</surname><given-names>M.J.</given-names></name><name><surname>Cretney</surname><given-names>E.</given-names></name><name><surname>Takeda</surname><given-names>K.</given-names></name><name><surname>Wiltrout</surname><given-names>R.H.</given-names></name><name><surname>Sedger</surname><given-names>L.M.</given-names></name><name><surname>Kayagaki</surname><given-names>N.</given-names></name><name><surname>Yagita</surname><given-names>H.</given-names></name><name><surname>Okumura</surname><given-names>K.</given-names></name></person-group><year>2001</year><article-title>Tumor necrosis factor&#x02013;related apoptosis-inducing ligand (TRAIL) contributes to interferon &#x003b3;&#x02013;dependent natural killer cell protection from tumor metastasis</article-title>.<source>J. Exp. Med.</source><volume>193</volume>:<fpage>661</fpage>&#x02013;<lpage>670</lpage><pub-id pub-id-type="pmid">11257133</pub-id></mixed-citation></ref><ref id="bib24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeda</surname><given-names>K.</given-names></name><name><surname>Hayakawa</surname><given-names>Y.</given-names></name><name><surname>Van Kaer</surname><given-names>L.</given-names></name><name><surname>Matsuda</surname><given-names>H.</given-names></name><name><surname>Yagita</surname><given-names>H.</given-names></name><name><surname>Okumura</surname><given-names>K.</given-names></name></person-group><year>2000</year><article-title>Critical contribution of liver natural killer T cells to a murine model of hepatitis</article-title>.<source>Proc. Natl. Acad. Sci. USA.</source><volume>97</volume>:<fpage>5498</fpage>&#x02013;<lpage>5503</lpage><pub-id pub-id-type="pmid">10792025</pub-id></mixed-citation></ref><ref id="bib23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeda</surname><given-names>K.</given-names></name><name><surname>Hayakawa</surname><given-names>Y.</given-names></name><name><surname>Smyth</surname><given-names>M.J.</given-names></name><name><surname>Kayagaki</surname><given-names>N.</given-names></name><name><surname>Yamaguchi</surname><given-names>N.</given-names></name><name><surname>Kakuta</surname><given-names>S.</given-names></name><name><surname>Iwakura</surname><given-names>Y.</given-names></name><name><surname>Yagita</surname><given-names>H.</given-names></name><name><surname>Okumura</surname><given-names>K.</given-names></name></person-group><year>2001</year><article-title>Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells</article-title>.<source>Nat. Med.</source><volume>7</volume>:<fpage>94</fpage>&#x02013;<lpage>100</lpage><pub-id pub-id-type="pmid">11135622</pub-id></mixed-citation></ref><ref id="bib25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toyabe</surname><given-names>S.</given-names></name><name><surname>Seki</surname><given-names>S.</given-names></name><name><surname>Iiai</surname><given-names>T.</given-names></name><name><surname>Takeda</surname><given-names>K.</given-names></name><name><surname>Shirai</surname><given-names>K.</given-names></name><name><surname>Watanabe</surname><given-names>H.</given-names></name><name><surname>Hiraide</surname><given-names>H.</given-names></name><name><surname>Uchiyama</surname><given-names>M.</given-names></name><name><surname>Abo</surname><given-names>T.</given-names></name></person-group><year>1997</year><article-title>Requirement of IL-4 and liver NK1+ T cells for concanavalin A-induced hepatic injury in mice</article-title>.<source>J. Immunol.</source><volume>159</volume>:<fpage>1537</fpage>&#x02013;<lpage>1542</lpage><pub-id pub-id-type="pmid">9233653</pub-id></mixed-citation></ref><ref id="bib26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trautwein</surname><given-names>C.</given-names></name><name><surname>Rakemann</surname><given-names>T.</given-names></name><name><surname>Brenner</surname><given-names>D.A.</given-names></name><name><surname>Streetz</surname><given-names>K.</given-names></name><name><surname>Licato</surname><given-names>L.</given-names></name><name><surname>Manns</surname><given-names>M.P.</given-names></name><name><surname>Tiegs</surname><given-names>G.</given-names></name></person-group><year>1998</year><article-title>Concanavalin A-induced liver cell damage: activation of intracellular pathways triggered by tumor necrosis factor in mice</article-title>.<source>Gastroenterology.</source><volume>114</volume>:<fpage>1035</fpage>&#x02013;<lpage>1045</lpage><pub-id pub-id-type="pmid">9558294</pub-id></mixed-citation></ref><ref id="bib27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trinchieri</surname><given-names>G.</given-names></name></person-group><year>2003</year><article-title>Interleukin-12 and the regulation of innate resistance and adaptive immunity</article-title>.<source>Nat. Rev. Immunol.</source><volume>3</volume>:<fpage>133</fpage>&#x02013;<lpage>146</lpage><pub-id pub-id-type="pmid">12563297</pub-id></mixed-citation></ref><ref id="bib28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vivier</surname><given-names>E.</given-names></name><name><surname>Tomasello</surname><given-names>E.</given-names></name><name><surname>Baratin</surname><given-names>M.</given-names></name><name><surname>Walzer</surname><given-names>T.</given-names></name><name><surname>Ugolini</surname><given-names>S.</given-names></name></person-group><year>2008</year><article-title>Functions of natural killer cells</article-title>.<source>Nat. Immunol.</source><volume>9</volume>:<fpage>503</fpage>&#x02013;<lpage>510</lpage><pub-id pub-id-type="pmid">18425107</pub-id></mixed-citation></ref><ref id="bib29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>S.J.</given-names></name><name><surname>Wang</surname><given-names>P.</given-names></name><name><surname>Tsabary</surname><given-names>G.</given-names></name><name><surname>Chen</surname><given-names>Y.H.</given-names></name></person-group><year>2004</year><article-title>Critical roles of TRAIL in hepatic cell death and hepatic inflammation</article-title>.<source>J. Clin. Invest.</source><volume>113</volume>:<fpage>58</fpage>&#x02013;<lpage>64</lpage><pub-id pub-id-type="pmid">14702109</pub-id></mixed-citation></ref><ref id="bib30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>C.</given-names></name><name><surname>Ma</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Guo</surname><given-names>L.</given-names></name><name><surname>Zhu</surname><given-names>Z.</given-names></name><name><surname>Stoops</surname><given-names>J.</given-names></name><name><surname>Eaker</surname><given-names>A.E.</given-names></name><name><surname>Johnson</surname><given-names>C.J.</given-names></name><name><surname>Strom</surname><given-names>S.</given-names></name><name><surname>Michalopoulos</surname><given-names>G.K.</given-names></name><etal/></person-group><year>2007</year><article-title>Lack of Fas antagonism by Met in human fatty liver disease</article-title>.<source>Nat. Med.</source><volume>13</volume>:<fpage>1078</fpage>&#x02013;<lpage>1085</lpage><pub-id pub-id-type="pmid">17704785</pub-id></mixed-citation></ref></ref-list><fn-group><fn><p>Abbreviations used: ConA, concanavalin A; HCC, hepatocellular carcinoma; IHC, immunohistochemistry; JNK, c-Jun N-terminal kinase; MNC, mononuclear cell; mRNA, messenger RNA; TRAIL, TNF-related apoptosis-inducing ligand.</p></fn></fn-group></back></article>